FINWIRES · TerminalLIVE
FINWIRES

$NXTS

2 stories mentioning NXTSUpdated 81d ago

Every FINWIRES story that references NXTS, newest first.

What's the latest news on NXTS?

Wire

Top Midday Decliners

Wheeler Real Estate Investment Trust (WHLR) said in a regulatory filing that it is marketing 35 of its 59 properties for sale and has engaged CBRE's National Retail Partners to pursue a portfolio transaction.Shares slumped 32%, with intraday trading volume of more than 375,000 versus a daily average of roughly 315,000.Nexentis Technologies (NXTS) said it is offering 410,998 shares at $7.056 a share to some institutional investors. It will also issue warrants to buy up to 410,998 shares to the investors.Shares sank 52% following a surge in intraday trading volume to over 1.7 million from a daily average of about 1.2 million.Carnival (CCL) provided a fiscal Q3 earnings outlook below Wall Street's estimates, though the cruise operator posted a surprise profit rise in Q2 and forecast robust demand and booking trends.Shares declined 5.1%, with intraday trading volume of over 26.5 million against a daily average of about 27.8 million.Price: $2.56, Change: $-1.24, Percent Change: -32.63%

$CCL$NXTS$WHLR
Wire

Top Midday Gainers

Nexentis Technologies (NXTS) said Monday its subsidiary, MitoCareX Bio, has entered into an engagement with Boltz, an AI research lab, to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier proteins of interest to MitoCareX's pipeline.Shares jumped over 200% as trading volume catapulted to over 55 million from a daily average of about 208,000.AbbVie (ABBV) agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion, the companies said Monday.Shares of Apogee soared 47%, with intraday trading volume of over 47.1 million against a daily average of about 975,000.Definium Therapeutics (DFTX) reported positive topline results from a phase 3 Emerge study of DT120 orally disintegrating tablet in major depressive disorder.RBC Capital raised its price target to $57 from $36, while maintaining its outperform rating.Shares surged 52% amid a jump in intraday trading volume to over 16 million from a daily average of roughly 1.9 million.Price: $15.55, Change: $+10.47, Percent Change: +206.08%

$ABBV$APGE$DFTX$NXTS

Track with the FINWIRES app suite